Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro   Niosi Marco   Vecchio Blanco Camillo Del   Loguercio Carmela  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite

Non-alcoholic fatty liver disease: a massive problem

By Day Christopher P  

Clinical Medicine, Vol. 11, Iss. 2, 2011-04 ,pp. : 176-178

Royal College Of Physicians

Access to resources Recommend Favorite

Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome

By Moscatiello Simona   Di Luzio Raffaella   Sasdelli Anna Simona   Marchesini Giulio  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 17, 2011-12 ,pp. : 2657-2672

Informa Healthcare

Access to resources Recommend Favorite

Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 18, Iss. 6, 2018-11 ,pp. : 547-554

Bentham Science Publishers

Access to resources Recommend Favorite

Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease

By  

Current Pharmaceutical Design, Vol. 19, Iss. 29, 2013-09 ,pp. : 5193-5218

Bentham Science Publishers

Access to resources Recommend Favorite